Evolent Health, Inc. (NYSE:EVH) Shares Bought by Royce & Associates LP

Royce & Associates LP lifted its position in shares of Evolent Health, Inc. (NYSE:EVH) by 130.5% during the fourth quarter, Holdings Channel reports. The firm owned 576,200 shares of the technology company’s stock after acquiring an additional 326,200 shares during the quarter. Royce & Associates LP’s holdings in Evolent Health were worth $6,482,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new position in Evolent Health during the fourth quarter worth approximately $31,000. AlphaQuest LLC grew its position in shares of Evolent Health by 21,650.0% during the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after acquiring an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust grew its position in shares of Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after acquiring an additional 2,358 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of Evolent Health in the 4th quarter valued at $61,000. Finally, KBC Group NV raised its position in Evolent Health by 124.6% in the 4th quarter. KBC Group NV now owns 6,741 shares of the technology company’s stock valued at $76,000 after purchasing an additional 3,739 shares during the last quarter.

Insider Activity at Evolent Health

In related news, CEO Seth Blackley acquired 55,225 shares of Evolent Health stock in a transaction dated Thursday, March 6th. The shares were acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the transaction, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at $6,867,575.17. The trade was a 7.81 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Diane Holder acquired 2,735 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average price of $9.33 per share, with a total value of $25,517.55. Following the transaction, the director now owns 70,584 shares in the company, valued at $658,548.72. This represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 74,000 shares of company stock valued at $666,315. 1.60% of the stock is owned by corporate insiders.

Evolent Health Trading Up 1.6 %

NYSE:EVH opened at $10.15 on Wednesday. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $10.09 and a 200-day simple moving average of $16.51. The company has a market capitalization of $1.18 billion, a PE ratio of -12.37 and a beta of 1.49.

Evolent Health (NYSE:EVH) last announced its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, equities research analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

EVH has been the topic of a number of recent research reports. Truist Financial dropped their price objective on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Stephens dropped their price target on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 21st. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Oppenheimer lowered their target price on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. Finally, UBS Group dropped their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.